Shernan G Holtan
Overview
Explore the profile of Shernan G Holtan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
2528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Holtan S, Bolanos-Meade J, Al Malki M, Wu J, Kitko C, Reshef R, et al.
J Clin Oncol
. 2025 Jan;
43(8):912-918.
PMID: 39752608
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) results in superior GVHD-free, relapse-free survival (GRFS)...
2.
Pidala J, Holtan S, Walton K, Kim J, Cao B, Elmariah H, et al.
Blood
. 2024 Jul;
144(22):2295-2307.
PMID: 39046783
Our phase 1 graft-versus-host disease (GVHD) prevention trial of JAK2 inhibitor, pacritinib (PAC; recommended phase 2 dose: 100 mg orally twice a day on day 0 to +70) plus sirolimus...
3.
Dimitrov M, Merkle S, Cao Q, Tryon R, Vercellotti G, Holtan S, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):1005.e1-1005.e17.
PMID: 39002862
Background: Dyskeratosis congenita/telomere biology disorders (DC/TBD) often manifest as bone marrow failure (BMF) or myelodysplastic syndrome (MDS). Allogeneic hematopoietic cell transplant (alloHCT) rescues hematologic complications, but radiation and alkylator-based conditioning...
4.
Rashidi A, Ebadi M, Rehman T, Elhusseini H, Kazadi D, Halaweish H, et al.
Cancer Res Commun
. 2024 May;
4(6):1454-1466.
PMID: 38767452
Significance: Post-FMT expansion of Faecalibacterium, associated with donor microbiota engraftment, predicted a higher risk for aGVHD in alloHCT recipients. Although Faecalibacterium is a commensal genus with gut-protective and anti-inflammatory properties...
5.
Herzog S, Shanley R, Holtan S, MacMillan M, Weisdorf D, Jurdi N
Transplant Cell Ther
. 2024 May;
30(7):688.e1-688.e9.
PMID: 38734182
Post-transplantation cyclophosphamide (PTCy) following hematopoietic cell transplantation (HCT) has emerged as standard of care for graft-versus-host disease (GVHD) prevention in adult patients without increasing malignant relapse. We previously defined acute...
6.
Jurdi N, Herzog S, Shanley R, Holtan S, MacMillan M, Weisdorf D
Transplant Cell Ther
. 2024 Mar;
30(6):616-625.
PMID: 38479549
Response to treatment of chronic graft-versus-host disease (cGVHD) may help predict prognosis and outcomes. We hypothesized that the response of cGVHD to treatment and the ability to taper immunosuppression define...
7.
Rashidi A, Ebadi M, Rehman T, Elhusseini H, Kazadi D, Halaweish H, et al.
Gut Microbes
. 2024 Mar;
16(1):2327442.
PMID: 38478462
In small series, third-party fecal microbiota transplantation (FMT) has been successful in decolonizing the gut from clinically relevant antibiotic resistance genes (ARGs). Less is known about the short- and long-term...
8.
Weisdorf D, Jurdi N, Holtan S
Best Pract Res Clin Haematol
. 2023 Dec;
36(4):101520.
PMID: 38092477
Options for GVHD prophylaxis after allogeneic hematopoietic cell transplantation can best be chosen by understanding the pathophysiology of GVHD. Interventions to limit T cell activation, expansion and subsequent tissue injury...
9.
Rashidi A, Ebadi M, Rehman T, Elhusseini H, Kazadi D, Halaweish H, et al.
Clin Cancer Res
. 2023 Oct;
29(23):4920-4929.
PMID: 37787998
Purpose: Intestinal microbiota disruptions early after allogeneic hematopoietic cell transplantation have been associated with increased risk for acute GVHD (aGVHD). In our recent randomized phase II trial of oral, encapsulated,...
10.
Holtan S, Jurdi N, Rashidi A, Betts B, Demorest C, Galvin J, et al.
Haematologica
. 2023 Sep;
109(5):1557-1561.
PMID: 37706330
No abstract available.